The green form asks the doctor to specify the "Reason for stopping" the drug being monitored if treatment was stopped. Thus, the ranked "Reasons for stopping" (in terms of the number of reports of each event) is another source for generating signals and can be compared with the ranked IDs for the first month of therapy in each individual patient. As examples, data for the most frequently reported events with the two anti-epileptic drugs, lamotrigine and vigabatrin, are given in Table 26.3.
In general, there appears to be a high degree of correlation between these two sets of values. These values can be used to compare drugs within one therapeutic class: for example with anti-epileptic drugs it shows that rash is the most frequently reported event likely to be a drug side effect with lamotrigine, whereas rash is far less common with vigabatrin; similarly, respiratory tract infection (which occurs month in and month out in all cohorts and which is, with many drugs, unlikely to be related to either the drug or disease being treated) is fairly common among the ID values but
Was this article helpful?